Streetbeat News

Stock Prices

SLAM

SLAM Corp. is transitioning from Nasdaq to OTC Markets but will continue trading under the same ticker symbols. The company remains committed to its business combination with Lynk Global, expecting to list on Nasdaq upon completion.

Portfolio Pulse from Benzinga Newsdesk

August 26, 2024 | 8:10 pm

LESL

Leslie's, Inc. has announced the appointment of Jason McDonell as the new CEO, effective September 9, 2024, following the departure of Mike Egeck. John Strain will serve as interim CEO. The company reaffirms its fiscal 2024 outlook.

Portfolio Pulse from Benzinga Newsdesk

August 26, 2024 | 8:08 pm

NTBL

Notable Labs has announced its plan to initiate a Phase 2 program for Volasertib in the coming months. This development could have implications for the company's future growth and stock performance.

Portfolio Pulse from Benzinga Newsdesk

August 26, 2024 | 8:08 pm

AVSC

IJR

IWM

VB

VTWO

Kevin Dreyer from Gabelli Funds suggests that small cap stocks, particularly those in the Russell 2000 index, are trading at a significant discount compared to large caps and are poised for a strong rally. This shift is attributed to the Federal Reserve's anticipated interest rate cuts. ETFs like iShares Russell 2000 ETF (IWM), Vanguard Russell 2000 ETF (VTWO), and Avantis U.S Small Cap Equity ETF (AVSC) are highlighted as ways to gain exposure to small caps.

Portfolio Pulse from Surbhi Jain

August 26, 2024 | 8:07 pm

AURA

Aura Biosciences will present Phase 2 study data on bel-sar for treating early-stage choroidal melanoma at the Retina Society Annual Meeting in 2024.

Portfolio Pulse from Benzinga Newsdesk

August 26, 2024 | 8:07 pm

DCTH

Delcath Systems announced the publication of an independent study on its CHEMOSAT Hepatic Delivery System, showing high efficacy and safety in treating liver tumors. The study reported a 91% disease control rate and highlighted the importance of repeated treatments.

Portfolio Pulse from Benzinga Newsdesk

August 26, 2024 | 8:05 pm

LBPH

Longboard Pharmaceuticals is set to present promising data on its drug Bexicaserin at the 15th Annual European Epilepsy Congress. The data highlights the drug's safety, efficacy, and therapeutic potential for treating developmental and epileptic encephalopathies. A Phase 3 program is planned to start this year.

Portfolio Pulse from Benzinga Newsdesk

August 26, 2024 | 8:03 pm

OXY

Occidental Petroleum (NYSE:OXY) has seen unusual options activity, with a significant bearish sentiment among investors. This activity suggests potential upcoming changes for the company. Analysts have mixed ratings, with price targets ranging from $65 to $76.

Portfolio Pulse from Benzinga Insights

August 26, 2024 | 8:01 pm

FTAI

FTAI Aviation (NASDAQ:FTAI) has significantly outperformed the market over the past 5 years, with an annualized return of 57.18%. A $1000 investment in FTAI 5 years ago would now be worth $9,618.23, highlighting the power of compounded returns.

Portfolio Pulse from Benzinga Insights

August 26, 2024 | 8:00 pm

KLAC

KLA (NASDAQ:KLAC) has significantly outperformed the market over the past 5 years, with an annualized return of 40.11%. A $100 investment in KLAC 5 years ago would now be worth $545.58, highlighting the power of compounded returns.

Portfolio Pulse from Benzinga Insights

August 26, 2024 | 8:00 pm